COVID-19 mRNA vaccine-associated encephalopathy, myocarditis, and thrombocytopenia with excellent response to methylprednisolone: A case reportShort communication Published on 2022-07-012022-10-05 Journal: Journal of neuroimmunology [Category] 바이오마커, 진단, [키워드] adverse event Autoimmune BNT162b2 Case report cause clinical Clinical features clinician Complication Convulsion COVID-19 COVID-19 vaccination described Diagnostic Criteria effective strategy Encephalitis Encephalopathy female Fever immune Laboratory Methylprednisolone mRNA myocarditis notable pandemic of COVID-19 Pathogenesis Patient Pfizer-BioNTech mRNA vaccine Pfizer-BioNTech mRNA vaccine (BNT162b2) Research responsible SARS-CoV-2 second dose significantly the vaccine thought thrombocytopenia vaccination Vaccine-associated encephalopathy [DOI] 10.1016/j.jneuroim.2022.577883 [Article Type] Short communication
A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine ResponseCOVID-19 백신의 4차 접종은 최적의 백신 반응을 보이지 않는 고형 장기 이식 수혜자들 사이에서 오미크론 변이체의 중화를 유도하지 않습니다Article Published on 2022-07-012022-09-11 Journal: Transplantation [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome angiotensin angiotensin-converting enzyme 2 anti-receptor-binding domain Anti-spike anti-spike antibody anti-Spike IgG Antibody Units binding antibody units booster vaccinations change Cohort coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine Delta delta variant domain dose ELISA full-length spike protein Health Organization healthy controls high risk Humoral response humoral responses IgG immune evasion Immunoglobulin increase Infection interquartile range Intervention Live virus median multiplex neutralization neutralizing capacity omicron Omicron variant Protective recipient respiratory response Seropositivity significantly increased significantly lower Solid solid organ solid organ transplant Spike proteins surrogate the vaccine Transplant Vaccination strategy Vaccine vaccine dose vaccine strain variant VoC VOCs was measured Wilcoxon signed-rank test World Health Organization [DOI] 10.1097/TP.0000000000004140 PMC 바로가기 [Article Type] Article
SARS-CoV-2 variants and the global pandemic challenged by vaccine uptake during the emergence of the Delta variant: A national survey seeking vaccine hesitancy causesSARS-CoV-2 변종과 Delta 변종 출현 중 백신 섭취로 도전받는 세계적 대유행: 백신 주저성을 찾는 전국 조사Article Published on 2022-07-012022-09-11 Journal: Journal of infection and public health [Category] COVID19(2023년), SARS, 변종, [키워드] Analysis cause children collected conducted contribute COVID-19 COVID-19 infection COVID-19 vaccination COVID-19 vaccine COVID-19 vaccine hesitancy COVID-19 vaccine uptake cross-sectional survey Delta delta variant Effectiveness effort emergence family history females global pandemic Health healthcare worker herd immunity Hesitancy infected with COVID-19 information less Measures media men Ministry of Health misinformation much lower Multivariate analysis National NEWS P-value pandemic parent parental parents participant Participants Public receive reported SARS-CoV-2 SARS-CoV-2 Delta variant SARS-CoV-2 variant SARS-CoV-2 variants Saudi Arabia Saudi Arabia national survey. seeking social media social media platform social media platforms Sociodemographic Spread subject the vaccine vaccinate vaccination Vaccination Status Vaccine Vaccine hesitancy variable variant variants with COVID-19 women [DOI] 10.1016/j.jiph.2022.06.007 PMC 바로가기 [Article Type] Article
Adverse events and breakthrough infections associated with COVID-19 vaccination in the Indian population인도 인구에서 COVID-19 예방 접종과 관련된 부작용 및 획기적인 감염Article Published on 2022-07-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, [키워드] Administered Adverse adverse event adverse events adverse-events affected age analyzed approval Breakthrough infection breakthrough infections combating competency Complete concerning conducted consequence Council COVID-19 determine Effectiveness Ethical approval event Factor female females fraction Health higher risk ICMR Immunity inclusion criteria individual individuals Infection information Informed consent male Medical research Microsoft Excel Missing data morbidity Odds ratio Older age Participants Prevent provided questionnaire Research response Retrospective study SARS-CoV-2 SARS-COV-2 infection Stata statistical difference statistical differences status the vaccine vaccination Vaccine Variability variants of SARS-CoV-2 were excluded with COVID-19 [DOI] 10.1002/jmv.27708 PMC 바로가기 [Article Type] Article
Patients’ Perspectives on Emergency Department COVID-19 Vaccination and Vaccination Messaging Through Randomized VignettesRandomized Controlled Trial Published on 2022-07-012022-10-04 Journal: Public health reports (Washington, D.C. : 1974) [Category] 임상, [키워드] 95% CI age approach black Boston Care center Cincinnati Community conducted COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine cross-sectional survey Department Emergency emergency department female had no Health highest hospital hypothetical Influenza Intention multisite offer outcome participant Participants Patient patient population patients preventive intervention randomization Randomized receive the vaccine university vaccination Vaccine Vaccine hesitancy vaccine-hesitant [DOI] 10.1177/00333549221085580 PMC 바로가기 [Article Type] Randomized Controlled Trial
T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccineB 세포 림프종 환자에서 COVID-19 mRNA 백신을 여러 번 접종한 후 SARS-CoV-2 및 Omicron 변이체에 대한 T 세포 반응Case Reports Published on 2022-07-012022-09-11 Journal: Journal for immunotherapy of cancer [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibody Antibody Response B cell B cells CD4 CD8 COVID-19 COVID-19 infections develop disease severity dose expected healthy subject healthy subjects Hematologic malignancy hematologic neoplasms humoral Immune escape immune system immunology Immunosuppression implication initial Lymphocytes lymphoma Messenger RNA mRNA mRNA vaccine multiple dose Neoplasms omicron Patient Patients with cancer protective immunity response SARS-CoV-2 SARS-CoV-2 virus T cell T cell response T cells T-lymphocytes the patient the SARS-CoV-2 virus the vaccine vaccination Vaccination strategy Vaccine Vaccines variant Viral Viral transmission while [DOI] 10.1136/jitc-2022-004953 PMC 바로가기 [Article Type] Case Reports
The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humansResearch article Published on 2022-07-012022-10-05 Journal: Thérapie [Category] 임상, [키워드] Administered administration African age approach AstraZeneca AstraZeneca COVID-19 vaccine Blood ChAdOx1 nCoV-19 clinical development clinical trials conducted coronavirus disease country COVID-19 COVID-19 vaccine Denmark described Effectiveness Efficacy EMA Europe European European Medicines Agency groups Human humans immunogenicity data information initial lack limit MHRA observational study Occurrence positive Safety shown supported the vaccine thrombotic Thrombotic thrombocytopenia triggered UK Medicine union Vaccine WHO World Health Organization [DOI] 10.1016/j.therap.2022.07.003 [Article Type] Research article
Optimal Timing of COVID-19 Vaccination in the Peri-Transplant Period: A Single Institution Case SeriesArticle Published on 2022-07-012022-11-15 Journal: Transplantation proceedings [Category] 진단, [키워드] antibody Antibody Response attrition booster dose coronavirus 2 COVID-19 detectable dose first dose Follow-up General population help Immunosuppressed Immunosuppression Infection institution investigated mRNA vaccines Organ transplant outcome Patient patients receiving recent recipient respiratory Sery susceptible the vaccine vaccination [DOI] 10.1016/j.transproceed.2022.01.021 PMC 바로가기
Antibody response to the messenger RNA-1273 vaccine (Moderna) in liver transplant recipients간 이식 환자에서 메신저 RNA-1273 백신(모더나)에 대한 항체 반응Article Published on 2022-07-012022-09-12 Journal: Hepatology communications [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Administered anti-S anti-S IgG antibody cause clinical coronavirus coronavirus disease COVID-19 COVID-19 infection develop dose evaluated examined Factor first vaccination Follow-up General population Hepatitis IgG Immunoglobulin Immunological response immunosuppressive include interquartile range laboratory data liver Liver transplantation Logistic regression LTR LTRs median median age men Messenger RNA Moderna MOST Most patient mRNA mRNA-1273 vaccine mRNA-based vaccine Odds ratio Patient positive predict receiving recipient recipients regimen response RNA-1273 SARS-CoV-2 Serologic response shown tested the spike protein the vaccine university Vaccine vaccine dose [DOI] 10.1002/hep4.1937 PMC 바로가기 [Article Type] Article
Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia항-CD19 키메라 항원 수용체 T 세포 유도 B 세포 무형성증이 있는 젊은 환자에서 SARS-CoV-2 백신 접종에 대한 면역 반응Article Published on 2022-07-012022-09-11 Journal: Transplantation and cellular therapy [Category] COVID19(2023년), MERS, SARS, 바이오마커, 변종, 진단, 치료기술, [키워드] Acute lymphoblastic leukemia acute respiratory syndrome acute respiratory syndrome coronavirus advent adverse events age Anti-CD19 Anti-CD19 CAR T cell-induced B cell aplasia anti-S Antigen antigen receptor aplasia B cell CAR CAR T cell therapy CD19 CD4 CD4/CD8 Cell therapy cellular immunity chimeric antigen receptor Cohort coronavirus coronavirus disease coronavirus disease 19 COVID-19 Cytometry deficiency diagnosed disease Endpoint Exacerbation exhibited expected flow cytometry grade 3 Graft-versus-host disease GVHD healthy healthy controls humoral Humoral response humoral responses Immune cell immune response Immunoglobulin Immunoglobulin G incidence individual induce Infection leukemia Lymphoblastic leukemia lymphocyte Lymphocyte count Lymphocyte subsets mRNA vaccine Mutation Omicron variant outcome Patient precursor primary endpoint Prospective Study PROTECT protective effect recipient Relapse respiratory response risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination second dose secondary Secondary endpoints Seroconversion severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Spike protein subsequent T cell T cell response T cell responses T cells T-cell the patient the vaccine therapy treated vaccination Vaccine [DOI] 10.1016/j.jtct.2022.04.017 PMC 바로가기 [Article Type] Article